AbbVies Business Development Cancer Plans Not Put Off By Stemcentrx Disappointments

AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments

At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty...

More From BioPortfolio on "AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments"